Skin Cancer Awareness Month: Highlighting our open access skin cancer research
Skin Cancer Awareness Month and to help raise awareness of skin cancer, our Editors across a number of open access oncology journals have developed a collection of articles to showcase some of the latest research in the field. Once you have read the research, take the quiz and share your results by tagging @OncoBioMed.
© Alexander Raths / stock.adobe.com
May marks the beginning of
Skin Cancer Awareness Month and today is Melanoma Monday. In recognition of these, we are proud to present a dedicated quiz and the following skin cancer research that has published within our open access oncology journal portfolio.
It is a common misconception that skin cancer and melanoma are one and the same but melanoma is just
one type of skin cancer. It is also the deadliest type of skin cancer and is currently ranked the 19, though that varies widely by country. th most common cancer worldwide
In the UK for example, it is the
5 and in Australia, it is the th most common cancer third most common. Though anyone can develop melanoma, these variations by country are largely because fair-skinned people are at a far greater risk for developing melanoma.
Rates of melanoma also differ by sex as
men are at a greater risk of both developing and dying from the disease. Reasons for this disparity include the tendency for men to work outdoors more than women and for women to use moisturizers/cosmetics with SPF more often than men.
Other types of skin cancers are basal cell carcinomas and squamous cells carcinomas. These are very common and are highly treatable. To put things in perspective, it is estimated that more people are diagnosed with skin cancer (including all types) in the US each year
than all other cancers combined.
As a global health issue, continued research on skin cancer is of paramount significance particularly regarding risk assessment and diagnostics, cellular pathways, therapeutics, and biomarkers. The articles in this collection have been curated by our oncology journal Editors and include some of the latest research in the field in each of these categories.
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
Activation and overexpression of the aryl hydrocarbon receptor contribute to cutaneous squamous cell carcinomas: an immunohistochemical study
Discovery of KIRREL as a biomarker for prognostic stratification of patients with thin melanoma
Eosinophil-cationic protein – a novel liquid prognostic biomarker in melanoma
Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
Acidic microenvironment plays a key role in human melanoma progression through a sustained exosome mediated transfer of clinically relevant metastatic molecules
Inhibition of skin carcinogenesis by suppression of NF-κB dependent ITGAV and TIMP-1 expression in IL-32γ overexpressed condition
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
Isolation and characterization of two canine melanoma cell lines: new models for comparative oncology
Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb
SOX9 is a dose-dependent metastatic fate determinant in melanoma
TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4
Risk assessment and diagnostics
Are prognostic indices for brain metastases of melanoma still valid in the stereotactic era?
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin
Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma
Fabry disease and incidence of cancer
Multifocal gastric adenocarcinoma in a patient with LRBA deficiency
Predominance of triple wild-type and IGF2R mutations in mucosal melanomas
Role of postoperative radiotherapy in dermatofibrosarcoma protuberans: a propensity score-matched analysis
TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness
Vitamin D axis and its role in skin carcinogenesis: a comprehensive review
(Arg)9-SH2 superbinder: a novel promising anticancer therapy to melanoma by blocking phosphotyrosine signaling
18F–FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma
Anti-cancer effect of dung beetle glycosaminoglycans on melanoma
Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
Effects of radiation on the metastatic process
Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma
Isoliquiritigenin suppresses human melanoma growth by targeting miR-301b/LRIG1 signaling
Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells
Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits
Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib
Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs
Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies
Tackling malignant melanoma epigenetically: histone lysine methylation
Targeted radiotherapy of pigmented melanoma with 131I-5-IPN
Vitexin compound 1, a novel extraction from a Chinese herb, suppresses melanoma cell growth through DNA damage by increasing ROS levels
Articles from the following journals have been included in this collection:
Applied Cancer Research , Biomarker Research , BMC Cancer , Clinical Epigenetics , Clinical Proteomics , Cancer Imaging , Diagnostic Pathology , Experimental Hematology & Oncology , Journal for ImmunoTherapy of Cancer , Journal of Experimental & Clinical Cancer Research , Journal of Hematology & Oncology , Lipids in Health and Disease , Molecular Cytogenetics , Molecular Medicine , Orphanet Journal of Rare Diseases , Radiation Oncology .
Now that you’ve read the research, why not test your knowledge of skin cancer with our
Skin Cancer Awareness Quiz?